

# Non-Muscle Invasive Bladder Cancer Market Report 2034: Epidemiology, Therapies, Latest Approvals by DelveInsight

Non-Muscle Invasive Bladder Cancer companies are Hoffmann-La Roche, Pfizer, Bristol-Myers Squibb, Johnson & Johnson, CG Oncology, ImmunityBio, and others.

LAS VEGAS, NEVADA, UNITED STATES, June 26, 2024 /EINPresswire.com/ -- DelveInsight's "Non-Muscle Invasive Bladder Cancer Market Insights, Epidemiology, and Market Forecast-2034" report offers an in-depth

understanding of the Non-Muscle Invasive Bladder Cancer, historical and forecasted epidemiology as well as the Non-Muscle Invasive Bladder Cancer market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Non-Muscle Invasive Bladder Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; [Non-Muscle Invasive Bladder Cancer Market Forecast](#)

Some of the key facts of the Non-Muscle Invasive Bladder Cancer Market Report:


The Non-Muscle Invasive Bladder Cancer market size is anticipated to grow with a significant CAGR during the study period (2020-2034).

The total NMIBC market size in the US was estimated to be USD 1,700 million in 2023, which is expected to grow during the forecast period (2024–2034).

NMIBC is a clinically heterogeneous group of cancers with a wide range of recurrence and progression probabilities that depend on several clinical and pathologic factors.

The current treatment regimen includes surgery, intravesical immunotherapy (BCG), and intravesical chemotherapy.

The standard care treatment for intermediate- and high-risk NMIBCs is a transurethral resection of the bladder tumor (TURBT) followed by intravesical Bacillus Calmette–Guerin (BCG)



instillations with induction and maintenance therapy for up to 3 years.

There are only two approved drugs for the treatment of NMIBC, namely KEYTRUDA (pembrolizumab) and ADSTILADRIN (nadofaragene firadenovec-vncg), which were approved in 2020 and 2022, respectively by the FDA. Since then, both drugs have been approved in the United States only.

Long before the COVID pandemic fueled the supply chain crisis, there was a shortage of BCG. BCG has long been the go-to initial treatment for high-risk NMIBC. The continuing BCG shortage has forced doctors to rely on other treatments for their patients with high-risk NMIBC. Among the alternatives they have turned to is a combination of two chemotherapy drugs, gemcitabine and docetaxel.

Gene therapy is an option with promising potential in HR-NMIBC. Oncolytic viral therapy is becoming more popular, particularly with the FDA's approval of nadofaragene firadenovec-vcng.

TLD-1433, combined with the TLC-3200 medical laser system, pioneers a personalized Ruthenium-based PhotoDynamic compound for BCG-unresponsive NMIBC, including CIS and papillary Ta or T1 tumors. This groundbreaking technology innovates NMIBC treatment and marks a transformative shift in medical technology paradigms.

Protara's TARA-002 exhibits a strong mechanism of action and offers clear advantages in overcoming the challenges related to BCG manufacturing.

TOKYO-172 is a predominantly used BCG strain in Japan.

The growing array of novel therapeutic agents for individuals with NMIBC presents challenges in determining the optimal treatment and sequence, given the diverse mechanisms of action and varying levels of efficacy. Customized treatment strategies are recommended, relying on a comprehensive understanding of disease characteristics, available treatments, and patient attributes and identifying and validating prognostic and predictive biomarkers.

The pipeline of NMIBC is strong with promising therapies like CG0070 (CG Oncology), Anktiva (ImmunityBio), Sasanlimab (Pfizer), EG-70 (enGene), UGN-102 (Urogen), Ruvidar/TLD-1433 (Theralase) and others.

In 2023, in the 7MM the total diagnosed prevalent cases of NMIBC were ~1,500,000.

Key Non-Muscle Invasive Bladder Cancer Companies: Hoffmann-La Roche, Pfizer, Bristol-Myers Squibb, AstraZeneca, UroGen Pharma, Johnson & Johnson, CG Oncology, ImmunityBio, Theralase Technologies, Protara Therapeutics, enGene, NanOlogy, Asieris Pharmaceutical, and others  
Key Non-Muscle Invasive Bladder Cancer Therapies: ADSTILADRIN (nadofaragene firadenovec), and others

The Non-Muscle Invasive Bladder Cancer market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Non-Muscle Invasive Bladder Cancer pipeline products will significantly revolutionize the Non-Muscle Invasive Bladder Cancer market dynamics.

## Non-Muscle Invasive Bladder Cancer Overview

Non-muscle-invasive bladder cancer (NMIBC) is a type of bladder cancer where the tumor is restricted to the innermost layer of the bladder wall, without penetrating the muscular layer.

This early stage of bladder cancer is quite common and is often seen as a superficial growth, manifesting as papillary tumors or carcinoma in situ. Given its tendency to recur or progress, NMIBC necessitates careful monitoring and treatment, which typically includes transurethral resection of the bladder tumor (TURBT) and subsequent therapies delivered directly into the bladder, such as Bacillus Calmette-Guérin (BCG) immunotherapy or chemotherapy. Regular cystoscopies and adherence to established guidelines are crucial for effective management and monitoring.

Diagnosing NMIBC involves cystoscopy and tissue biopsy. An initial cystoscopic examination, which may include biopsies of any visible tumors, is usually conducted in an outpatient setting. Flexible cystoscopy, facilitated by a topical anesthetic lubricant, helps minimize discomfort during the procedure, especially for male patients. While transurethral resection is the standard initial treatment for most NMIBC cases, a thorough cystoscopic examination of the entire urethra and bladder is essential before proceeding with the resection. However, if a bladder lesion is detected during the evaluation of hematuria via CT or MRI, surgeons may opt to perform TURBT immediately. During the resection, all significant tumors should be removed and labeled, with their location, configuration (papillary or flat), size, and number documented in a consistent manner to guide future surveillance and assess treatment outcomes.

High-risk NMIBC, though less advanced than muscle-invasive bladder cancer, can exhibit considerable aggressiveness. Management strategies for high-risk NMIBC include regular cystoscopies for monitoring, intravesical immunotherapy with BCG, and in severe cases, removal of the bladder (cystectomy). Despite the potential for a positive prognosis, treatment can be intensive and may require years of follow-up. The main treatment options for NMIBC include surgery, BCG immunotherapy, and chemotherapy delivered into the bladder. Surgery, whether alone or in combination with other treatments, is a common approach. TURBT is a frequently used surgical technique to remove visible cancer cells, ensuring a comprehensive treatment approach.

## Non-Muscle Invasive Bladder Cancer Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Non-Muscle Invasive Bladder Cancer Epidemiology Segmentation:

The Non-Muscle Invasive Bladder Cancer market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

Total Prevalence of Non-Muscle Invasive Bladder Cancer

Prevalent Cases of Non-Muscle Invasive Bladder Cancer by severity

Gender-specific Prevalence of Non-Muscle Invasive Bladder Cancer

Diagnosed Cases of Episodic and Chronic Non-Muscle Invasive Bladder Cancer

Download the report to understand which factors are driving Non-Muscle Invasive Bladder Cancer epidemiology trends @ [Non-Muscle Invasive Bladder Cancer Epidemiology Forecast](#)

## Non-Muscle Invasive Bladder Cancer Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Non-Muscle Invasive Bladder Cancer market or expected to get launched during the study period. The analysis covers Non-Muscle Invasive Bladder Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Non-Muscle Invasive Bladder Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

## Non-Muscle Invasive Bladder Cancer Key Companies

Hoffmann-La Roche, Pfizer, Bristol-Myers Squibb, AstraZeneca, UroGen Pharma, Johnson & Johnson, CG Oncology, ImmunityBio, Theralase Technologies, Protara Therapeutics, enGene, NanOlogy, Asieris Pharmaceutical

## Non-Muscle Invasive Bladder Cancer Therapies

ADSTILADRIN (nadofaragene firadenovec), KEYTRUDA (pembrolizumab), TECENTRIQ (atezolizumab), Sasanlimab (PF-06801591)

Discover more about therapies set to grab major Non-Muscle Invasive Bladder Cancer market share @ [Non-Muscle Invasive Bladder Cancer Treatment Landscape](#)

## Scope of the Non-Muscle Invasive Bladder Cancer Market Report:

Study Period: 2020–2034

Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

Key Non-Muscle Invasive Bladder Cancer Companies: Dana-Farber Cancer Institute, Huabo Biopharm Co., Ltd., Beijing Scitech-Mq Pharmaceuticals, Oxford BioMedica, Hutchison Medipharma Limited, Takeda, Amgen, Novartis, AVEO Pharmaceuticals, Inc., Merck Sharp &

Dohme LLC, Pfizer, Calithera Biosciences, Inc, AbbVie, Bristol-Myers Squibb, Abbott, SCRI Development Innovations, LLC, Astellas Pharma Inc, and others

Key Non-Muscle Invasive Bladder Cancer Therapies: Bevacizumab, HB0025, ST-1898 tablets, Trovax, fruquintinib+sintilimab, Cabozantinib, AMG 102, Pazopanib, tivozanib (AV-951), Belzutifan, Temsirolimus (CCI-779), CB-839, ABT-869, Nivolumab, ABT-510/Thrombospondin-1 mimetic, bevacizumab, CP-461, and others

Non-Muscle Invasive Bladder Cancer Therapeutic Assessment: Non-Muscle Invasive Bladder Cancer current marketed and Non-Muscle Invasive Bladder Cancer emerging therapies

Non-Muscle Invasive Bladder Cancer Market Dynamics: Non-Muscle Invasive Bladder Cancer market drivers and Non-Muscle Invasive Bladder Cancer market barriers

Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

Non-Muscle Invasive Bladder Cancer Unmet Needs, KOL's views, Analyst's views, Non-Muscle Invasive Bladder Cancer Market Access and Reimbursement

To know more about Non-Muscle Invasive Bladder Cancer companies working in the treatment market, visit @ Non-Muscle Invasive Bladder Cancer Clinical Trials and Therapeutic Assessment

## Table of Contents

1. Non-Muscle Invasive Bladder Cancer Market Report Introduction
2. Executive Summary for Non-Muscle Invasive Bladder Cancer
3. SWOT analysis of Non-Muscle Invasive Bladder Cancer
4. Non-Muscle Invasive Bladder Cancer Patient Share (%) Overview at a Glance
5. Non-Muscle Invasive Bladder Cancer Market Overview at a Glance
6. Non-Muscle Invasive Bladder Cancer Disease Background and Overview
7. Non-Muscle Invasive Bladder Cancer Epidemiology and Patient Population
8. Country-Specific Patient Population of Non-Muscle Invasive Bladder Cancer
9. Non-Muscle Invasive Bladder Cancer Current Treatment and Medical Practices
10. Non-Muscle Invasive Bladder Cancer Unmet Needs
11. Non-Muscle Invasive Bladder Cancer Emerging Therapies
12. Non-Muscle Invasive Bladder Cancer Market Outlook
13. Country-Wise Non-Muscle Invasive Bladder Cancer Market Analysis (2020–2034)
14. Non-Muscle Invasive Bladder Cancer Market Access and Reimbursement of Therapies
15. Non-Muscle Invasive Bladder Cancer Market Drivers
16. Non-Muscle Invasive Bladder Cancer Market Barriers
17. Non-Muscle Invasive Bladder Cancer Appendix
18. Non-Muscle Invasive Bladder Cancer Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:

## Non-Muscle Invasive Bladder Cancer Pipeline

"Non-Muscle Invasive Bladder Cancer Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Non-Muscle Invasive Bladder Cancer market. A detailed picture of the Non-Muscle Invasive Bladder Cancer pipeline landscape is provided, which includes the disease overview and Non-Muscle Invasive Bladder Cancer treatment guidelines.

## Non-Muscle Invasive Bladder Cancer Epidemiology

DelveInsight's 'Non-Muscle Invasive Bladder Cancer Epidemiology Forecast to 2034' report delivers an in-depth understanding of the disease, historical and forecasted Non-Muscle Invasive Bladder Cancer epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

## Latest Reports by DelveInsight

Adalimumab Biosimilar Market | Arbovirus Infection Market | Artificial Pancreas Device System Market | Dental Equipment Market | Gluten Sensitivity Market | Hypothyroidism Market | Inflammatory Bowel Disease Market | Mayus Kinase Jak Inhibitors Market | Mild Dry Eye Market | Mucopolysaccharidosis Market | Oncolytic Virus Cancer Therapy Market | Pyoderma Gangrenosum Market | Transdermal Drug Delivery Devices Market | Intrathecal Pumps Market | Hedgehog Pathway Inhibitors Market | Yellow Fever Market | Laryngeal Cancer Market | Female Infertility Market | Gender Dysphoria Market | Chronic Brain Damage Market | Spain Healthcare Outlook Market | Malignant Fibrous Histiocytoma Market | Asthma Diagnostic Devices Market | Chronic Obstructive Pulmonary Disease Treatment Devices Market | Airway Management Devices Market | Cough Assist Devices Market | Pulse Oximeters Market | Hemodialysis Catheter Devices Market | Chronic Spontaneous Urticaria Market | Gender Dysphoria Market | Germany Healthcare Outlook | Biopsy Devices Pipeline Insight | Bacterial Conjunctivitis Market | Infliximab Biosimilar Insight | Eosinophilic Asthma Market | Cushing Syndrome Market | Functional Dyspepsia Market | Peripherally Inserted Central Catheters (PICC) Devices Market

## About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Kritika Rehani

DelveInsight Business Research LLP

+1 469-945-7679

[email us here](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/723079390>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.